Cleared Traditional

K170974 - BD FACSLyric Flow Cytometer (3-1, 4-2, 4-2-2 and 4-3-3 optical configurations), BD FACSuite Clinical Software, BD Multitest 6-Color Assays, BD Multitest 4-Color Assays, BD Multitest 6-Color TBNK (FDA 510(k) Clearance)

Jul 2017
Decision
91d
Days
Class 2
Risk

K170974 is an FDA 510(k) clearance for the BD FACSLyric Flow Cytometer (3-1, 4-2, 4-2-2 and 4-3-3 optical configurations), BD FACSuite Clinical Software, BD Multitest 6-Color Assays, BD Multitest 4-Color Assays, BD Multitest 6-Color TBNK. This device is classified as a Flow Cytometric Reagents And Accessories. (Class II - Special Controls, product code OYE).

Submitted by Becton, Dickinson and Company (San Jose, US). The FDA issued a Cleared decision on July 3, 2017, 91 days after receiving the submission on April 3, 2017.

This device falls under the Immunology FDA review panel. Regulated under 21 CFR 864.5220. To Identify And Classify Cells Or Other Particles In Suspension By Their Inherent Physical Properties Or Associated Fluorescent Molecules In Order To Provide Information About The Distribution Or Number Cells In Suspension Or Their Level Of Protein Expression. These Characteristics May Aid In The Diagnosis Of Conditions Such As Immunodeficiency And Cancer..

Submission Details

510(k) Number K170974 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received April 03, 2017
Decision Date July 03, 2017
Days to Decision 91 days
Submission Type Traditional
Review Panel Immunology (IM)
Summary Summary PDF

Device Classification

Product Code OYE — Flow Cytometric Reagents And Accessories.
Device Class Class II - Special Controls
CFR Regulation 21 CFR 864.5220
Definition To Identify And Classify Cells Or Other Particles In Suspension By Their Inherent Physical Properties Or Associated Fluorescent Molecules In Order To Provide Information About The Distribution Or Number Cells In Suspension Or Their Level Of Protein Expression. These Characteristics May Aid In The Diagnosis Of Conditions Such As Immunodeficiency And Cancer.